Table 2 Baseline and demographic characteristics
HIT-6 analysis population | MIDAS analysis population | |||||
|---|---|---|---|---|---|---|
Characteristic | Quarterly fremanezumab (n = 652) | Monthly fremanezumab (n = 664) | Placebo (n = 652) | Quarterly fremanezumab (n = 567) | Monthly fremanezumab (n = 575) | Placebo (n = 570) |
Age, years, mean (SD) | 43.6 (12.0) | 42.9 (11.9) | 43.7 (12.0) | 43.4 (11.4) | 44.5 (11.9) | 44.0 (11.9) |
Age category, n (%) | ||||||
18–45 years | 343 (53) | 376 (57) | 350 (54) | 303 (53) | 290 (50) | 305 (54) |
46–65 years | 293 (45) | 274 (41) | 290 (44) | 254 (45) | 272 (47) | 248 (44) |
> 65 years | 16 (2) | 14 (2) | 12 (2) | 10 (2) | 13 (2) | 17 (3) |
Sex, n (%) | ||||||
Female | 560 (86) | 570 (86) | 561 (86) | 480 (85) | 483 (84) | 478 (84) |
Male | 92 (14) | 94 (14) | 91 (14) | 87 (15) | 92 (16) | 26.3 (4.7) |
BMI, kg/m2, mean (SD) | 26.0 (4.9) | 26.0 (4.8) | 26.0 (4.7) | 26.0 (4.7) | 25.7 (4.8) | |
Migraine classification, n (%) | ||||||
CM | 545 (84) | 553 (83) | 541 (83) | 169 (30) | 174 (30) | 166 (29) |
EM | 107 (16) | 111 (17) | 111 (17) | 398 (70) | 401 (70) | 404 (71) |
Baseline HIT-6 score, mean (SD) | 64.3 (4.6) | 64.3 (4.5) | 64.1 (4.9) | – | – | – |
Baseline MIDAS score, mean (SD) | – | – | – | 51.4 (42.8) | 50.0 (44.7) | 49.2 (46.2) |